WO2006010838A3 - Products containing at least one anticancer active principle with low diffusion and an immunostimulatory active principle - Google Patents

Products containing at least one anticancer active principle with low diffusion and an immunostimulatory active principle Download PDF

Info

Publication number
WO2006010838A3
WO2006010838A3 PCT/FR2005/001612 FR2005001612W WO2006010838A3 WO 2006010838 A3 WO2006010838 A3 WO 2006010838A3 FR 2005001612 W FR2005001612 W FR 2005001612W WO 2006010838 A3 WO2006010838 A3 WO 2006010838A3
Authority
WO
WIPO (PCT)
Prior art keywords
active principle
immunostimulatory
low diffusion
products containing
anticancer
Prior art date
Application number
PCT/FR2005/001612
Other languages
French (fr)
Other versions
WO2006010838A2 (en
Inventor
Caroline Robert
Lluis Mir
Antoine Carpentier
Original Assignee
Roussy Inst Gustave
Centre Nat Rech Scient
Univ Paris Descartes
Oligovax
Caroline Robert
Lluis Mir
Antoine Carpentier
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP04292515A external-priority patent/EP1649859A1/en
Application filed by Roussy Inst Gustave, Centre Nat Rech Scient, Univ Paris Descartes, Oligovax, Caroline Robert, Lluis Mir, Antoine Carpentier filed Critical Roussy Inst Gustave
Priority to AU2005266225A priority Critical patent/AU2005266225A1/en
Priority to EP05783840A priority patent/EP1765361A2/en
Publication of WO2006010838A2 publication Critical patent/WO2006010838A2/en
Publication of WO2006010838A3 publication Critical patent/WO2006010838A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Abstract

The invention concerns products used in combination, for efficient treatment of tumors and more particularly of metastases. Said products contain at least one anticancer active principle with low diffusion and an immunostimulatory active principle selected from the group consisting of TLR ligands in the form of a combined preparation for simultaneous, separate or prolonged use, for treating benignant and malignant tumors and more particularly metastases, in an subject suffering from a tumor and subjected to electropermeabilization at said tumor or at an appropriate healthy tissue.
PCT/FR2005/001612 2004-06-25 2005-06-24 Products containing at least one anticancer active principle with low diffusion and an immunostimulatory active principle WO2006010838A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2005266225A AU2005266225A1 (en) 2004-06-25 2005-06-24 Products containing at least one anticancer active principle with low diffusion and an immunostimulatory active principle
EP05783840A EP1765361A2 (en) 2004-06-25 2005-06-24 Products containing at least one anticancer active principle with low diffusion and an immunostimulatory active principle

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP04291615.5 2004-06-25
EP04291615 2004-06-25
EP04292515.6 2004-10-22
EP04292515A EP1649859A1 (en) 2004-10-22 2004-10-22 Pharmaceutical compositions comprising at least one poorly diffusible anticancer drug and a olidodeoxynucleotide immunestimulant

Publications (2)

Publication Number Publication Date
WO2006010838A2 WO2006010838A2 (en) 2006-02-02
WO2006010838A3 true WO2006010838A3 (en) 2006-06-15

Family

ID=35515626

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR2005/001612 WO2006010838A2 (en) 2004-06-25 2005-06-24 Products containing at least one anticancer active principle with low diffusion and an immunostimulatory active principle

Country Status (3)

Country Link
EP (1) EP1765361A2 (en)
AU (1) AU2005266225A1 (en)
WO (1) WO2006010838A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006054129A1 (en) 2004-11-19 2006-05-26 Institut Gustave Roussy Improved treatment of cancer by double-stranded rna
FR2975600B1 (en) * 2011-05-24 2013-07-05 Assist Publ Hopitaux De Paris AGENTS FOR THE TREATMENT OF TUMORS
GB201408119D0 (en) 2014-05-08 2014-06-25 Univ Cork Method
WO2017023803A1 (en) 2015-07-31 2017-02-09 Regents Of The University Of Minnesota Modified cells and methods of therapy
US20200208111A1 (en) * 2016-06-09 2020-07-02 Branden S. Moriarity Genome-edited nk cell and methods of making and using

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999051259A2 (en) * 1998-04-03 1999-10-14 University Of Iowa Research Foundation Methods and products for stimulating the immune system using immunotherapeutic oligonucleotides and cytokines
US20020192184A1 (en) * 1999-03-19 2002-12-19 Carpentier Antoine F. Use of stabilized oligonucleotides for preparing a medicament with antitumor activity

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999051259A2 (en) * 1998-04-03 1999-10-14 University Of Iowa Research Foundation Methods and products for stimulating the immune system using immunotherapeutic oligonucleotides and cytokines
US20020192184A1 (en) * 1999-03-19 2002-12-19 Carpentier Antoine F. Use of stabilized oligonucleotides for preparing a medicament with antitumor activity

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
CARPENTIER A F ET AL: "Successful treatment of intracranial gliomas in rat by oligodeoxynucleotides containing CpG motifs.", CLINICAL CANCER RESEARCH : AN OFFICIAL JOURNAL OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH. JUN 2000, vol. 6, no. 6, June 2000 (2000-06-01), pages 2469 - 2473, XP002366692, ISSN: 1078-0432 *
CONNELL Y S ET AL: "ANTI-TUMOR ACTIVITY OF A CPG-CONTAINING OLIGODEOXYNUCLEOTIDE (ODN) IN ATHYMIC MICE", PROCEEDINGS OF THE 90TH ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH. PHILADELPHIA, PA, APRIL 10 - 14, 1999, PROCEEDINGS OF THE ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, PHILADELPHIA, PA : AACR, US, vol. VOL. 40, April 1999 (1999-04-01), pages 299, XP000857678 *
HECKELSMILLER K ET AL: "Combined dendritic cell- and CpG oligonucleotide-based immune therapy cures large murine tumors that resist chemotherapy", EUROPEAN JOURNAL OF IMMUNOLOGY, WEINHEIM, DE, vol. 32, no. 11, November 2002 (2002-11-01), pages 3235 - 3245, XP002322319, ISSN: 0014-2980 *
HECKELSMILLER K ET AL: "Peritumoral CpG DNA elicits a coordinated response of CD8 T cells and innate effectors to cure established tumors in a murine colon carcinoma model", JOURNAL OF IMMUNOLOGY, THE WILLIAMS AND WILKINS CO. BALTIMORE, US, vol. 169, no. 7, 1 October 2002 (2002-10-01), pages 3892 - 3899, XP002322318, ISSN: 0022-1767 *
MIR L M ET AL: "ELECTROCHEMOTHERAPY POTENTIATION OF ANTITUMOUR EFFECT OF BLEOMYCIN BY LOCAL ELECTRIC PULSES", EUROPEAN JOURNAL OF CANCER, PERGAMON PRESS, OXFORD, GB, vol. 27, no. 1, 1991, pages 68 - 72, XP000575541, ISSN: 0959-8049 *
WEIGEL BRENDA J ET AL: "CpG oligodeoxynucleotides potentiate the antitumor effects of chemotherapy or tumor resection in an orthotopic murine model of rhabdomyosarcoma.", CLINICAL CANCER RESEARCH : AN OFFICIAL JOURNAL OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH. 1 AUG 2003, vol. 9, no. 8, 1 August 2003 (2003-08-01), pages 3105 - 3114, XP002990544, ISSN: 1078-0432 *

Also Published As

Publication number Publication date
AU2005266225A1 (en) 2006-02-02
WO2006010838A2 (en) 2006-02-02
EP1765361A2 (en) 2007-03-28

Similar Documents

Publication Publication Date Title
WO2004113571A3 (en) Prostate specific genes and the use thereof as targets for prostate cancer therapy and diagnosis
WO2005118601A3 (en) Sulfonylethyl phosphorodiamidates for use in the treatment of cancer
WO2002080754A3 (en) Methods for using annexin for detecting cell death in vivo and treating associated conditions
WO2006113623A3 (en) Elimination of heterogeneous or mixed cell population in tumors
WO2005123908A3 (en) Novel cancer cell lines and uses thereof
WO2004070062A3 (en) Compositions and methods for diagnosing and treating cancers
TW200621240A (en) Cancer treatments
WO2002087555A3 (en) Use of bisphosphonates in the treatment of bone metastasis associated with prostate cancer
WO2001012199A3 (en) Methoxyamine potentiation of temozolomide anti-cancer activity
WO2006081510A3 (en) Methods for treating renal cell carcinoma
WO2003000928A3 (en) Methods for identification of cancer cell surface molecules and cancer specific promoters, and therapeutic uses thereof
SG160412A1 (en) Anti-igfr1 antibody therapeutic combinations
WO2007033023A3 (en) Compositions and methods for the diagnosis and therapy of bcl2-associated cancers
WO2001092581A8 (en) Compositions and methods for the therapy and diagnosis of ovarian cancer
WO2007008200A8 (en) Wortmannin analogs and methods of using same in combination with chemotherapeutic agents
WO2006027693A3 (en) Tumor specific genes and variant RNAS and uses thereof as targets for cancer therapy and diagnosis
WO2006010838A3 (en) Products containing at least one anticancer active principle with low diffusion and an immunostimulatory active principle
WO2008052054A3 (en) Synergism between activated immune cells and conventional cancer therapies
IL141550A0 (en) Methods and compositions for the prevention or treatment of cancer
WO2001077168A3 (en) Compositions and methods for the therapy and diagnosis of lung cancer
WO2003013431A3 (en) Compositions and methods for the therapy and diagnosis of breast cancer
MXPA04007443A (en) Novel, water-soluble porphyrin platinum compounds with high tumor selectivity and their use for the treatment of benign and malignant tumor diseases.
WO2001090152A3 (en) Compositions and methods for the therapy and diagnosis of breast cancer
ATE293991T1 (en) USE OF AN ENTEROBACTERIAL PROTEIN OMPA ASSOCIATED WITH THE PEPTIDE ßELAGIGILTVß FOR THE TREATMENT OF MELANOMA
MXPA05004920A (en) Combination comprising a cdk inhibitor and cisplatin.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

WWE Wipo information: entry into national phase

Ref document number: 2005783840

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2005266225

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2005266225

Country of ref document: AU

Date of ref document: 20050624

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2005266225

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2005783840

Country of ref document: EP